{"product_id":"pt141-10mg","title":"PT141 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/pt141-10mg_75877525-ff6d-45af-85f3-7693ae0ffcc1.png?v=1779537351\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003ePT141 is a research peptide studied for its potential effects on sexual function and arousal in both men and women. This 10mg vial is designed for laboratory and research purposes only. PT141 works through a different mechanism than traditional treatments, targeting melanocortin receptors in the brain rather than vascular pathways. Research suggests it may promote spontaneous desire and improve response regardless of psychological state. Each vial contains 10mg of lyophilized peptide powder. Intended for qualified researchers and educational use in controlled settings.\u003c\/p\u003e\n\u003cp\u003ePeptide Sequence: PT-141 (Bremelanotide analog) Molecular Weight: 1025.18 g\/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 10mg Storage: Keep refrigerated at 2–8°C. Protect from light. Reconstitution: Reconstitute with sterile water or bacteriostatic saline as needed for research applications. Research Use Only: Not for human consumption. For laboratory and qualified research purposes only.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C50H71N15O10 CAS Number: 189691-06-3 Amino Acid Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store lyophilized powder at 2–8°C in a refrigerator. Keep vial tightly sealed in its original container. Protect from light and moisture. Under these conditions, the peptide remains stable for up to 24 months. Storage After Reconstitution: Once reconstituted with sterile water or bacteriostatic saline, store the solution at 2–8°C. Reconstituted PT141 is stable for approximately 2–4 weeks when kept refrigerated and protected from light. For extended storage, freeze reconstituted solution at −20°C, where it remains viable for several months. Avoid repeated freeze-thaw cycles.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 (Bremelanotide) Origins: Derivation from Melanotan II\u003c\/strong\u003e\u003cbr\u003eHadley ME \u0026amp; Dorr RT. (2006). \u003cem\u003eMelanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.\u003c\/em\u003e Peptides, 27(4), 921–930. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.peptides.2005.01.029\"\u003ehttps:\/\/doi.org\/10.1016\/j.peptides.2005.01.029\u003c\/a\u003e\u003cbr\u003eReviews the development of melanocortin peptide analogues including the derivation of PT-141 (bremelanotide) from Melanotan II, detailing the structure–activity relationships that led to its cyclic heptapeptide design and selective melanocortin receptor profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMelanocortin Receptor Pharmacology: MC3R and MC4R\u003c\/strong\u003e\u003cbr\u003eWikberg JE, et al. (2000). \u003cem\u003eNew aspects on the melanocortins and their receptors.\u003c\/em\u003e Pharmacological Research, 42(5), 393–420. \u003ca href=\"https:\/\/doi.org\/10.1006\/phrs.2000.0725\"\u003ehttps:\/\/doi.org\/10.1006\/phrs.2000.0725\u003c\/a\u003e\u003cbr\u003eComprehensive review of the five melanocortin receptor subtypes (MC1R–MC5R), their tissue distribution, and signalling pathways — establishing the receptor pharmacology through which PT-141 exerts its central nervous system effects via MC3R and MC4R activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 and Central Mechanisms of Sexual Arousal\u003c\/strong\u003e\u003cbr\u003eMolinoff PB, et al. (2003). \u003cem\u003ePT-141: a melanocortin agonist for the treatment of sexual dysfunction.\u003c\/em\u003e Annals of the New York Academy of Sciences, 994, 96–102. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb03167.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb03167.x\u003c\/a\u003e\u003cbr\u003eCharacterises PT-141’s mechanism of action as a centrally acting melanocortin agonist, demonstrating that its pro-erectile and pro-arousal effects in preclinical models are mediated through hypothalamic MC4R activation rather than peripheral vascular pathways — distinguishing it mechanistically from PDE5 inhibitors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 Phase 2 Clinical Research in Male Subjects\u003c\/strong\u003e\u003cbr\u003eDiamond LE, et al. (2004). \u003cem\u003eA double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.\u003c\/em\u003e International Journal of Impotence Research, 16(1), 51–59. \u003ca href=\"https:\/\/doi.org\/10.1038\/sj.ijir.3901139\"\u003ehttps:\/\/doi.org\/10.1038\/sj.ijir.3901139\u003c\/a\u003e\u003cbr\u003eDouble-blind, placebo-controlled Phase 2 trial evaluating intranasal PT-141 pharmacokinetics and pharmacodynamics, demonstrating significant pro-erectile activity and establishing the compound’s safety and tolerability profile in a controlled clinical research setting.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBremelanotide (PT-141) in Female Sexual Dysfunction Research\u003c\/strong\u003e\u003cbr\u003eClayton AH, et al. (2016). \u003cem\u003eBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.\u003c\/em\u003e Women’s Health, 12(3), 325–337. \u003ca href=\"https:\/\/doi.org\/10.2217\/whe-2016-0018\"\u003ehttps:\/\/doi.org\/10.2217\/whe-2016-0018\u003c\/a\u003e\u003cbr\u003eRandomised, placebo-controlled dose-finding trial of bremelanotide (PT-141) in premenopausal women, providing key pharmacodynamic and tolerability data across dose ranges and establishing the research basis for melanocortin agonism in female sexual arousal disorder models.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248665878871,"sku":"P41","price":16.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/pt141-10mg_75877525-ff6d-45af-85f3-7693ae0ffcc1.png?v=1779537351","url":"https:\/\/www.mutantpeptides.com\/products\/pt141-10mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}